[go: up one dir, main page]

US20100256050A1 - Composition for preventing virus infection comprising poly-gamma-glutamic acid - Google Patents

Composition for preventing virus infection comprising poly-gamma-glutamic acid Download PDF

Info

Publication number
US20100256050A1
US20100256050A1 US12/678,027 US67802707A US2010256050A1 US 20100256050 A1 US20100256050 A1 US 20100256050A1 US 67802707 A US67802707 A US 67802707A US 2010256050 A1 US2010256050 A1 US 2010256050A1
Authority
US
United States
Prior art keywords
virus
pga
infection
gamma
glutamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/678,027
Inventor
Moon-Hee Sung
Chul Joong Kim
Haryoung Poo
Young-Ki Choi
Il Han Lee
Dai-Won Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
BioLeaders Corp
Original Assignee
BioLeaders Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioLeaders Corp filed Critical BioLeaders Corp
Assigned to KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, BIOLEADERS CORPORATION reassignment KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, YOUNG-KI, KIM, CHUL JOONG, LEE, IL HAN, POO, HARYOUNG, SUNG, MOON-HEE, YOO, DAI-WON
Publication of US20100256050A1 publication Critical patent/US20100256050A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.
  • viruses such as an influenza virus, inducing respiratory infection or systemic infection
  • Influenza virus belongs to the Orthomyxoviridae family, and has 8 RNA fragments, PB2, PB1, PA, HA, NP, NA, M and NS. It is basically composed of a virus envelope having lipid bilayer structure, and an interior nucleocapsid surrounded by external glycoprotein or RNA combined with nucleoprotein.
  • the internal layer of a virus envelope is mainly composed of matrix proteins, and the external layer thereof is composed of lipid materials mostly derived from a host.
  • HA hemagglutinin
  • NA neuraminidase
  • influenza virus induces a bad cold which is an acute respiratory disease, and symptoms thereof are shown after latent period of 1 ⁇ 5 days. Infected people show no symptom in the beginning, but later, they show symptoms such as fever, chill, ache, anorexia and the like. In some cases, it causes viral pneumonia, bacterial pneumonia and the like, which can lead to death. During the past 250 years, there were at least 10 major influenza pandemics, and influenza epidemics caused by type A virus occur at an interval of 2 ⁇ 3 years. Since flu (influenza) is a viral infection of the respiratory system, it is highly contagious and has a high ratio of inapparent infection so that many people are infected at one time.
  • influenza vaccine which is an inactivated vaccine mixed with various vaccines, has some side effects and lasts only for 3 ⁇ 6 months, so that children and old people, who are highly susceptible to influenza, should be vaccinated yearly against flu.
  • ⁇ -PGA Poly-gamma-glutamic acid
  • PGA is a mucous polymer produced by microorganisms.
  • PGA is produced from the genus Bacillus strain isolated from Chungkookjang (Korean traditional fermented soybean food prepared using rice-straw), Natto (Japanese traditional fermented soybean food), Kinema (fermented soybean food prepared in Nepal), etc.
  • ⁇ -PGA produced from the genus Bacillus strain is an edible, water-soluble, anionic and biodegradable polymer substance, which can be used as a raw material for humectants, moisturizers and cosmetics.
  • the present inventors obtained a patent relating to a method for producing ⁇ -PGA using a halophilic Bacillus subtilis var. chungkookjang that produces ⁇ -PGA with high molecular weight (Korean Patent Registration No. 500,796). Also, they obtained patents relating to an anticancer composition, an immune adjuvant and an immune enhancing agent, which contain ⁇ -PGA (Korean Patent Registration Nos. 496,606; 517,114; and 475,406).
  • the present inventors have made extensive efforts to develop a foodstuff additive, a functional food, and a pharmaceutical composition, which have no side effects, is not harmful to the human body and have an infection-inhibiting effect against viruses, such as influenza, inducing respiratory infection or systemic infection, and as a result, found that viral infection could be inhibited when a livestock, to which ⁇ -PGA is administered, was exposed to viral infection, thereby completing the present invention.
  • viruses such as influenza, inducing respiratory infection or systemic infection
  • ⁇ -PGA poly-gamma-glutamic acid
  • the present invention provides a pharmaceutical composition for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • the present invention provides a functional food for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • the present invention provides a feedstuff additive for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • FIG. 1 is a graph showing changes in the number of infected mice survived according to the days elapsed from infection.
  • FIG. 2 is a graph showing changes in the number of dead mice according to the days elapsed from infection.
  • FIG. 3 is a graph showing changes in virus titer in lung tissue of mice infected with virus according to the days elapsed from infection.
  • FIG. 4 is a graph showing the weight loss rate of mice infected with virus according to the days elapsed from infection.
  • FIG. 5 is a graph illustrating INF- ⁇ increase in macrophages by treatment with poly-gamma-glutamic acid.
  • the present invention relates to a pharmaceutical composition for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • poly-gamma-glutamic acid having an infection-inhibiting effect and a disease preventing effect it is preferable to use poly-gamma-glutamic acid having a molecular weight of 10 kDa ⁇ 15,000 kDa, and more preferably poly-gamma-glutamic acid having a high molecular weight of 3,000 kDa ⁇ 15,000 kDa
  • the virus may be a virus capable of inducing respiratory infection or systemic infection, and the virus is preferably an influenza virus.
  • the inventive pharmaceutical composition for inhibiting viral infection and preventing viral disease can be used to prevent a pandemic influenza, the flu, a cold, throat infection, bronchitis, or pneumonia, caused by the influenza virus.
  • ⁇ -PGA ⁇ -PGA based on 100 parts by weight of the inventive pharmaceutical composition for inhibiting virus infection
  • ⁇ -PGA content is less than 0.2 parts by weight, a virus infection-inhibiting effect cannot be anticipated and in the case where the ⁇ -PGA content is more than 2 parts by weight, an increase of an infection-inhibiting effect according to content increase cannot be anticipated as well as it causes a high cost and thus it is not economically efficient.
  • a dispersive formulation which can be used for spraying individual animals including human or large scale disinfection.
  • ethanol content used for the dispersive formulation is more than 50%, the poly-gamma-glutamic acid may be precipitated, and in the case of less than 1%, the viscosity increases so that dispersion may not occur, thus it is preferable to add ethanol at a concentration of 1 ⁇ 50%.
  • the present invention relates to a functional food for preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid.
  • the inventive functional food may be in the form of a powder, a granule, a tablet, a capsule, or a drink, and may contain flavor ingredients, natural carbohydrates, vitamins, minerals, flagrances, colorants, extenders, stabilizers, antiseptics, and the like.
  • the present invention relates to a feedstuff additive for preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid.
  • the inventive feedstuff additive can effectively prevent livestock infectious diseases, and can be fed to mammals such as cow, pig, rabbit, horse, goat, dog, cat, deer and the like, and fowl such as chicken, duck, turkey, quail and the like.
  • ⁇ -PGA ⁇ -PGA based on 100 parts by weight of the inventive feedstuff additive
  • PGA content is less than 0.2 parts by weight
  • a virus preventing effect cannot be anticipated
  • ⁇ -PGA content is more than 2 parts by weight
  • an increase of an infection-inhibiting effect according to content increase cannot be anticipated, which causes economic inefficiency due to high costs thereof.
  • a 5 L fermenter containing a 3 L basal medium for ⁇ -PGA production (GS medium containing 5% L-glutamic acid: 5% glucose, 1% (NH 4 ) 2 SO 4 , 0.27% KH 2 PO 4 , 0.42% Na 2 HPO 4 .12H 2 O, 0.05% NaCl, 0.3% MgSO 4 .7H 2 O, pH 6.8) was inoculated with 1% culture broth of Bacillus subtilis var chungkookjang (KCTC 0697BP) and then cultured at a stirring speed of 150 rpm, an air injection rate of 1 vvm and a temperature of 37° C. for 72 hours. Cells were removed from the culture broth after completion of the culture using a filter press, thus obtaining a ⁇ -PGA-containing sample solution.
  • GS medium containing 5% L-glutamic acid 5% glucose, 1% (NH 4 ) 2 SO 4 , 0.27% KH 2 PO 4 , 0.42% Na 2 HPO 4 .12H
  • mice Ten, 6-week-old male rats (159.76 ⁇ 199.27 g) and 10 female rats (121.60 ⁇ 138.80 g) were used, and the dose of ⁇ -PGA administered to individual rats was calculated on the basis of body weight measured on the day of administration after fasting. All rats were fasted for about 16 hours but had free access to drinking water before administration, and then they were subjected to forceful oral administration with a single dose of ⁇ -PGA by stomach tube using a disposable syringe (5 ml) having a catheter for oral administration attached thereto, followed by being fed a feedstuff 4 hours after administration.
  • a disposable syringe (5 ml) having a catheter for oral administration attached thereto
  • ⁇ -PGA 100 mg/ml of ⁇ -PGA was orally administered to 2 male rats and 2 female rats, respectively with a single dose of 20 ml/kg, and as a result, no dead rats were observed and thus 2000 mg/20 ml/kg was used as a single dose.
  • An expedient was administered to a control group at the same dose as that of the experimental group to which a test material is administered.
  • the dosage to be administered was set to 20 ml/kg.
  • H1N1 high pathogenicity influenza virus strain (A/Puerto Rico/8/34 (H1N1)) was isolated from a mouse which was donated by Prof. Choi, Young-Ki of microbiological laboratory, College of Medicine, Chungbuk National University to amplify in Madin-Darby canine kidney (MDCK) cells to use, and 6-week-old female Balb/C mice were used as experimental animals.
  • the isolated virus was diluted in antibiotic-containing PBS to inoculate into 10-day-old embryonated white laying hen's eggs, and then subjected to a stationary culture at 37° C. for 48 hours, from which the allantonic fluid was harvested and amplified virus was used.
  • MDCK cells grown in an alpha-MEM (minimum essential medium, Gibco, USA) medium containing penicillin and streptomycin, and 5% fetal bovine serum (FBS) in a 6 well cell culture plate were washed 3 times with PBS and diluted with a medium in which penicillin and streptomycin (hereinafter referred to as P/S) were contained and FBS was not contained, and then diluted virus was added to each well to infect cells, followed by culturing in a 37° C., 5% CO 2 incubator for 1 hour.
  • P/S penicillin and streptomycin
  • TPCK N-alpha-tosyl-L-phenylalanyl chloromethyl ketone treated-trypsin EDTA not containing FBS and an alpha-MEM medium containing P/S were added to each well to culture in a cell culture incubator. After 24 hours of incubation, the cell culture plate was washed with PBS and fixed using 0.1% noble agar containing medium.
  • the cultured plaques were inoculated into a 24 well plate, in which the prepared MDCK cells were cultured, at a density of one plaque per well, and 0.1% TPCK treated-trypsin EDTA not containing FBS and an alpha-MEM medium containing P/S were added to each well to culture in a cell incubator. After 48 hours of incubation, media collected from each well were centrifuged, and supernatant was infected in a MDCK cell-containing flask prepared by the same method as described above to culture 36 ⁇ 48 hours, and then the resulting culture broth was centrifuged, followed by transferring the resulting supernatant to a micro tube to store in a low temperature freezer ( ⁇ 80° C.) until use for animal experiments.
  • TPCK treated-trypsin EDTA not containing FBS and an alpha-MEM medium containing P/S were added to each well to culture in a cell incubator. After 48 hours of incubation, media collected from each well were centrifuged, and
  • mice to which influenza virus alone was intranasally administered, was used.
  • poly-gamma-glutamic acid ⁇ -PGA
  • ⁇ -PGA poly-gamma-glutamic acid
  • influenza virus was administered the next day, thus inhibiting viral infection.
  • mice were anesthetized using diethyl ether for 30 seconds, and then, 30 ⁇ l ⁇ -PGA (7,000 kDa) having a final concentration of 0.5% was administered to the nasal cavity of each mouse.
  • influenza virus was simultaneously administered to the mice together with the same amount of ⁇ -PGA.
  • mice As an experimental group 2, mice, to which ⁇ -PGA and influenza virus were simultaneously administered on the day when the experimental group 1 was infected with virus, was used. Constitution of the experimental groups are shown in Table 2.
  • the experimental animals were anesthetized using diethyl ether for 30 seconds to intranasally administer 30 ⁇ l of virus to each mouse, and in the groups administered volume A of virus, 2.5 ⁇ 10 5 EID 50 of virus was administered and in the groups administered volume B of virus, 1.25 ⁇ 10 5 EID 50 of virus was administered.
  • mice died on the 7th day after virus administration.
  • mice died on the 12th day after administration in the group administered volume A of virus.
  • mice survived more than 2 weeks after virus administration. It suggests that pre-administration of ⁇ -PGA induces immunity to inhibit viral infection, as well as simultaneous administration helps each individual mouse to survive.
  • HA Haemagglutination
  • the harvested lung tissue was immersed in PBS (500 ⁇ l) containing antibiotics and crushed with small metallic beads sterilized with steam of high-pressure and high-humidity for 3 minutes in a tissue homogenizer.
  • the crushed tissue was centrifuged to obtain supernatant and diluted by log 10 dilution, and then the diluted solution was inoculated into 10-day-old embryonated eggs of white laying hens.
  • the inoculated embryonated eggs were cultured at 37° C. for 48 hours to harvest the allantoic fluid.
  • 50 ⁇ l of the harvested allantoic fluid was added to the first well of a round-bottom 96 well plate, and next each well was log 2 diluted in the same volume of PBS, and then 50 ⁇ l PBS was discarded after dilution of the last well.
  • 50 ⁇ l of PBS containing 0.5% chicken erythrocytes was added to each well and allowed to react for 40 minutes at room temperature.
  • Each titer is the value calculated from log 10 dilution of inoculum solution (200 ⁇ l).
  • Titer is the value calculated from log 10 dilution of inoculum solution (200 ⁇ l).
  • the group administered volume A of virus showed a titer of 5.3
  • the group administered volume B of virus showed a titer of 5, and an increase or decrease in the titer was not shown since all mice died.
  • the group administered volume B of virus showed a gradual decrease in titer with the passage of time.
  • the titer was decreased a little in the experimental group 2.
  • administration of ⁇ -PGA helps an individual mouse overcome infectious disease caused by highly pathogenic virus.
  • titer decrease was higher in the group immunized with ⁇ -PGA 1 day before virus administration, suggesting that immunization with ⁇ -PGA induces resistance against virus.
  • Antibody titers in sera of mice according to dates and each group were measured by the following HI (Haemagglutination Inhibition) test.
  • the antibody titer against virus increased in the experimental group to which virus and ⁇ -PGA were simultaneously administered.
  • the experimental group 2 antibodies started to appear on the 13th day after administration, and increased until the 15th day.
  • antibodies started to appear on the 15th day.
  • the control group since all mice died on the 7th day, only the titer in specimens was measured and antibodies against virus were not shown.
  • the experimental group immunized with ⁇ -PGA the day before virus administration, antibodies were produced relatively late compared to the experimental group 2, but the experimental group 1 showed higher antibody production than that of the group to which ⁇ -PGA and virus were simultaneously administered.
  • the ⁇ -PGA according to the present invention had an immune enhancement effect against virus to inhibit viral infection.
  • H1N1 high pathogenicity influenza virus strain (A/Puerto Rico/8/34 (H1N1)) was isolated from a mouse which was donated by Prof. Choi, Young-Ki of microbiological laboratory, College of Medicine, Chungbuk National University to amplify in Madin-Darby canine kidney (MDCK) cells to use, and 6-week-old female Balb/C mice were used as experimental animals.
  • a control group was administered influenza virus alone, an experimental group 2 was administered ⁇ -PGA twice, and then administered influenza virus, and an experimental group 3 was simultaneously administered ⁇ -PGA and influenza virus.
  • Influenza virus and ⁇ -PGA were intranasally administered to experimental mice after mice were anesthetized with diethyl ether for 30 minutes, at this time, 30 ⁇ l ⁇ -PGA (7,000 kDa) with a final concentration of 0.5% was intranasally administered to each mouse, and 10 4 EID 50 (30 ⁇ l) of virus was administered.
  • mice per group were used in order to measure mortality rate, 18 mice were used in order to measure changes in the amount of virus according to dates, and 15 mice were used as a control group for the experiment, and changes in body weight were monitored on a daily basis in each group to measure weight change rates as a pathogen indicator.
  • mice in the control group, starting with the death of one mouse 1 week after virus administration, 3 mice died on the 9th day and, on the 12th day, 2 mice with severe pathogenicity remained alive. In the experimental groups 2 and 3, mice only showed mild disease symptoms, and survived more than 12 days after virus administration.
  • mice per group were euthanized at an interval of 2 days (on the 1st day, the 3rd day, the 5th day, the 7th day, the 9th day, and the 12th day after virus administration) to harvest lung tissue and serum of each mouse.
  • Each titer is the value calculated from log 10 dilution of inoculum solution (200 ⁇ l).
  • the virus titer showed the maximum value of 5.5 on the 5th day after administering virus in the control group and the experimental group 3.
  • the virus titer was relatively low on the first day after virus administration, increased until the 5th day, started to decrease after the 5th day of administration, rapidly decreased after the 7th day of administration, and virus was not detected anymore on the 12th day.
  • the titer was the same as that of the control group on the 5th day after administering virus, but started to decrease after the 5th day of administration, rapidly decreased on the 7th day after virus administration like the experimental group 2, and virus was not detected anymore on the 12th day. This suggests that the administered ⁇ -PGA helps an individual mouse to resist viral infection, and thus is effective for an individual mouse to overcome viral infection due to enhanced immunity.
  • weight changes were monitored on a daily basis in each group ( FIG. 4 ). Each value is expressed as a percentage of the decreased rate (weight measured after virus administration/weight measured before virus administration).
  • the poly-gamma-glutamic acid according to the present invention has an immune enhancement effect against influenza virus to inhibit viral infection.
  • interferon beta one of cytokines secreted by macrophages, which mediates innate immune reaction
  • RAW 264.7 (ATCC TIB-71), which is a macrophage cell line of Balb/c mouse, was suspended in a DMEM (added with 100 U/ml penicillin-streptomycin, 10% FBS) medium and dispensed into a 6 well plate at a density of 5 ⁇ 10 5 cells/well to culture in a CO 2 incubator for 12 hours, and then, ⁇ -PGA (7,000 kDa) was diluted to concentrations of 0.1% and 0.5% in a DMEM medium containing no FBS, respectively, to culture for 12 hours.
  • ⁇ -PGA is highly effective to induce macrophage activation, and the macrophage activation is ⁇ -PGA-concentration dependent.
  • ⁇ -PGA induces the secretion of INF- ⁇ secreted by macrophages, which is an indicator of the activation of macrophages playing an important role in immune reaction and virus growth inhibition activity.
  • the present invention has the effect of providing the composition containing ⁇ -PGA as an effective ingredient, which can be used as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (γ-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.
The composition containing poly-gamma-glutamic acid as an effective ingredient according to the present invention, is effective for use as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.

Description

    TECHNICAL FIELD
  • The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.
    • BACKGROUND ART
  • Influenza virus belongs to the Orthomyxoviridae family, and has 8 RNA fragments, PB2, PB1, PA, HA, NP, NA, M and NS. It is basically composed of a virus envelope having lipid bilayer structure, and an interior nucleocapsid surrounded by external glycoprotein or RNA combined with nucleoprotein. The internal layer of a virus envelope is mainly composed of matrix proteins, and the external layer thereof is composed of lipid materials mostly derived from a host. Among them, two proteins constituting a coat protein, i.e., hemagglutinin (hereinafter referred to as HA) and neuraminidase (hereinafter referred to as NA) are important immunogens in inducing immune antibodies, and they are characterized by being transformed through the process of antigenic shift and drift. Since this transformation of an influenza virus enables the virus to avoid the immune system against other influenza virus of the same subtypes, and generally, immunity induced by an influenza virus only lasts for a short period of time and thus immunity should be induced against a predicted pandemic virus every time. Influenzas are divided into three groups A, B, and C.
  • An influenza virus induces a bad cold which is an acute respiratory disease, and symptoms thereof are shown after latent period of 1˜5 days. Infected people show no symptom in the beginning, but later, they show symptoms such as fever, chill, ache, anorexia and the like. In some cases, it causes viral pneumonia, bacterial pneumonia and the like, which can lead to death. During the past 250 years, there were at least 10 major influenza pandemics, and influenza epidemics caused by type A virus occur at an interval of 2˜3 years. Since flu (influenza) is a viral infection of the respiratory system, it is highly contagious and has a high ratio of inapparent infection so that many people are infected at one time. It frequently occurs in children of 5˜9 years old and in old people of more than 55 years old, and usually breaks out the most between fall and spring. Since it is hard to control influenza infections and most of the influenza infections are inapparent infections, it is not necessary to isolate patients. An influenza vaccine, which is an inactivated vaccine mixed with various vaccines, has some side effects and lasts only for 3˜6 months, so that children and old people, who are highly susceptible to influenza, should be vaccinated yearly against flu.
  • Poly-gamma-glutamic acid (γ-PGA) is a mucous polymer produced by microorganisms. Specifically, PGA is produced from the genus Bacillus strain isolated from Chungkookjang (Korean traditional fermented soybean food prepared using rice-straw), Natto (Japanese traditional fermented soybean food), Kinema (fermented soybean food prepared in Nepal), etc. γ-PGA produced from the genus Bacillus strain is an edible, water-soluble, anionic and biodegradable polymer substance, which can be used as a raw material for humectants, moisturizers and cosmetics. Recently, studies on the use of γ-PGA in developing materials substituting for non-degradable polymers and heat-resistant plastics by esterification, and producing water-soluble fibers and membranes, are being actively performed in developed countries.
  • Meanwhile, the present inventors obtained a patent relating to a method for producing γ-PGA using a halophilic Bacillus subtilis var. chungkookjang that produces γ-PGA with high molecular weight (Korean Patent Registration No. 500,796). Also, they obtained patents relating to an anticancer composition, an immune adjuvant and an immune enhancing agent, which contain γ-PGA (Korean Patent Registration Nos. 496,606; 517,114; and 475,406).
  • Accordingly, the present inventors have made extensive efforts to develop a foodstuff additive, a functional food, and a pharmaceutical composition, which have no side effects, is not harmful to the human body and have an infection-inhibiting effect against viruses, such as influenza, inducing respiratory infection or systemic infection, and as a result, found that viral infection could be inhibited when a livestock, to which γ-PGA is administered, was exposed to viral infection, thereby completing the present invention.
    • SUMMARY OF THE INVENTION
  • Therefore, it is a main object of the present invention to provide a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection to prevent diseases, which comprise poly-gamma-glutamic acid (γ-PGA) having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.
  • To achieve the above object, the present invention provides a pharmaceutical composition for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • In addition, the present invention provides a functional food for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • Also, the present invention provides a feedstuff additive for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • The above and other objects, features and embodiments of the present invention will be more clearly understood, from the following detailed description and accompanying claims.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing changes in the number of infected mice survived according to the days elapsed from infection.
  • FIG. 2 is a graph showing changes in the number of dead mice according to the days elapsed from infection.
  • FIG. 3 is a graph showing changes in virus titer in lung tissue of mice infected with virus according to the days elapsed from infection.
  • FIG. 4 is a graph showing the weight loss rate of mice infected with virus according to the days elapsed from infection.
  • FIG. 5 is a graph illustrating INF-β increase in macrophages by treatment with poly-gamma-glutamic acid.
    •  DETAILED DESCRIPTION OF THE INVENTION, AND PREFERRED EMBODIMENTS
  • In one aspect, the present invention relates to a pharmaceutical composition for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
  • In the present invention, as the poly-gamma-glutamic acid having an infection-inhibiting effect and a disease preventing effect, it is preferable to use poly-gamma-glutamic acid having a molecular weight of 10 kDa˜15,000 kDa, and more preferably poly-gamma-glutamic acid having a high molecular weight of 3,000 kDa˜15,000 kDa
  • In the present invention, the virus may be a virus capable of inducing respiratory infection or systemic infection, and the virus is preferably an influenza virus.
  • The inventive pharmaceutical composition for inhibiting viral infection and preventing viral disease can be used to prevent a pandemic influenza, the flu, a cold, throat infection, bronchitis, or pneumonia, caused by the influenza virus.
  • It is preferable to contain 0.2˜2 parts by weight of γ-PGA based on 100 parts by weight of the inventive pharmaceutical composition for inhibiting virus infection, and in the case where the γ-PGA content is less than 0.2 parts by weight, a virus infection-inhibiting effect cannot be anticipated and in the case where the γ-PGA content is more than 2 parts by weight, an increase of an infection-inhibiting effect according to content increase cannot be anticipated as well as it causes a high cost and thus it is not economically efficient.
  • In case of preparing a composition comprising 0.1˜2.0 parts by weight of γ-PGA in the form of liquid formulation containing ethanol, it is possible to prepare a dispersive formulation which can be used for spraying individual animals including human or large scale disinfection. In the case where ethanol content used for the dispersive formulation is more than 50%, the poly-gamma-glutamic acid may be precipitated, and in the case of less than 1%, the viscosity increases so that dispersion may not occur, thus it is preferable to add ethanol at a concentration of 1˜50%.
  • In another aspect, the present invention relates to a functional food for preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid.
  • The inventive functional food may be in the form of a powder, a granule, a tablet, a capsule, or a drink, and may contain flavor ingredients, natural carbohydrates, vitamins, minerals, flagrances, colorants, extenders, stabilizers, antiseptics, and the like.
  • In still another aspect, the present invention relates to a feedstuff additive for preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid.
  • The inventive feedstuff additive can effectively prevent livestock infectious diseases, and can be fed to mammals such as cow, pig, rabbit, horse, goat, dog, cat, deer and the like, and fowl such as chicken, duck, turkey, quail and the like.
  • It is preferable to contain 0.2˜2 parts by weight of γ-PGA based on 100 parts by weight of the inventive feedstuff additive, and in the case where the PGA content is less than 0.2 parts by weight, a virus preventing effect cannot be anticipated and in the case where the γ-PGA content is more than 2 parts by weight, an increase of an infection-inhibiting effect according to content increase cannot be anticipated, which causes economic inefficiency due to high costs thereof.
    • EXAMPLES
  • Hereinafter, the present invention will be described in more detail by examples. It is to be understood, however, that these examples are for illustrative purpose only and are not construed to limit the scope of the present invention.
    • Example 1 Production of γ-PGA Having Ultra High Molecular Weight and Measurement of Molecular Weight Thereof
  • A 5 L fermenter containing a 3 L basal medium for γ-PGA production (GS medium containing 5% L-glutamic acid: 5% glucose, 1% (NH4)2SO4, 0.27% KH2PO4, 0.42% Na2HPO4.12H2O, 0.05% NaCl, 0.3% MgSO4.7H2O, pH 6.8) was inoculated with 1% culture broth of Bacillus subtilis var chungkookjang (KCTC 0697BP) and then cultured at a stirring speed of 150 rpm, an air injection rate of 1 vvm and a temperature of 37° C. for 72 hours. Cells were removed from the culture broth after completion of the culture using a filter press, thus obtaining a γ-PGA-containing sample solution.
  • 2N sulfuric acid solution was added to the γ-PGA-containing sample solution and left to stand at 10° C. for 12 hours to collect a γ-PGA precipitate. The collected precipitate was washed with a sufficient amount of distilled water to obtain γ-PGA using a Nutsche filter. The obtained γ-PGA was measured for molecular weight using GPC (gel permeation column), and as a result, it was confirmed that γ-PGA having a molecular weight of 1˜45,000 kDa was produced, and then separated according to molecular weight to collect γ-PGA having an average molecular weight of 7,000 kDa. The collected γ-PGA was used in the following examples.
    • Example 2 Toxicity Test Results Upon Oral Administration of γ-PGA
  • In order to examine the safety upon oral administration of γ-PGA, toxicity test upon a single oral administration of poly-gamma-glutamic acid using rats was performed by Biotoxtech Co., Ltd., an institute approved by GLP (Good Laboratory Practice) in accordance with Biotoxtech Standard Operating Procedures (SOPs), Good Laboratory Practice (GLP) regulations and test guideline.
  • Ten, 6-week-old male rats (159.76˜199.27 g) and 10 female rats (121.60˜138.80 g) were used, and the dose of γ-PGA administered to individual rats was calculated on the basis of body weight measured on the day of administration after fasting. All rats were fasted for about 16 hours but had free access to drinking water before administration, and then they were subjected to forceful oral administration with a single dose of γ-PGA by stomach tube using a disposable syringe (5 ml) having a catheter for oral administration attached thereto, followed by being fed a feedstuff 4 hours after administration.
  • As a preliminary experiment, 100 mg/ml of γ-PGA was orally administered to 2 male rats and 2 female rats, respectively with a single dose of 20 ml/kg, and as a result, no dead rats were observed and thus 2000 mg/20 ml/kg was used as a single dose. An expedient was administered to a control group at the same dose as that of the experimental group to which a test material is administered. The dosage to be administered was set to 20 ml/kg.
  • As a result, as shown in Table 1, death and general symptoms caused by oral administration of γ-PGA were not observed during the observation period. During the observation period, it was seen that the body weight of male and female rats increased in the control group and the experimental group to which a test material is administered. Autopsy results did not reveal any abnormal findings visible to the naked eye in male and female rats of the control group and the experimental group to which a test material is administered. From the result of a single oral administration of γ-PGA to rats, general symptoms and death caused by the test material were not observed so that it was determined that the fatal dose of γ-PGA was more than 2000 mg/kg in female and male rats.
  • TABLE 1
    Group/ Approximate
    Dose No. of Day after treatment Mortality lethal dose
    Sex (mg/kg) animals 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 (dead/total) (mg/kg)
    Male G1 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% >2000
    0 (0/5)
    G2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0%
    2000 (0/5)
    Female G1 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% >2000
    0 (0/5)
    G2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0%
    2000 (0/5)
    • Example 3 Immune Enhancement Effect 1 of γ-PGA Against Influenza Virus
  • In the present example, in order to examine an infection-inhibiting effect of poly-gamma-glutamic acid specific to avian influenza virus, the animal's death, virus proliferation, and antibody production in experimental animals infected with influenza virus, were analyzed.
    • (1) Preparation of Virus
  • As influenza virus used as a pathogen, H1N1 high pathogenicity influenza virus strain (A/Puerto Rico/8/34 (H1N1)) was isolated from a mouse which was donated by Prof. Choi, Young-Ki of microbiological laboratory, College of Medicine, Chungbuk National University to amplify in Madin-Darby canine kidney (MDCK) cells to use, and 6-week-old female Balb/C mice were used as experimental animals.
  • Isolation of pure virus was carried out as follows.
  • Firstly, the isolated virus was diluted in antibiotic-containing PBS to inoculate into 10-day-old embryonated white laying hen's eggs, and then subjected to a stationary culture at 37° C. for 48 hours, from which the allantonic fluid was harvested and amplified virus was used.
  • Secondly, MDCK cells grown in an alpha-MEM (minimum essential medium, Gibco, USA) medium containing penicillin and streptomycin, and 5% fetal bovine serum (FBS) in a 6 well cell culture plate, were washed 3 times with PBS and diluted with a medium in which penicillin and streptomycin (hereinafter referred to as P/S) were contained and FBS was not contained, and then diluted virus was added to each well to infect cells, followed by culturing in a 37° C., 5% CO2 incubator for 1 hour. 0.1% TPCK (N-alpha-tosyl-L-phenylalanyl chloromethyl ketone) treated-trypsin EDTA not containing FBS and an alpha-MEM medium containing P/S were added to each well to culture in a cell culture incubator. After 24 hours of incubation, the cell culture plate was washed with PBS and fixed using 0.1% noble agar containing medium.
  • The cultured plaques were inoculated into a 24 well plate, in which the prepared MDCK cells were cultured, at a density of one plaque per well, and 0.1% TPCK treated-trypsin EDTA not containing FBS and an alpha-MEM medium containing P/S were added to each well to culture in a cell incubator. After 48 hours of incubation, media collected from each well were centrifuged, and supernatant was infected in a MDCK cell-containing flask prepared by the same method as described above to culture 36˜48 hours, and then the resulting culture broth was centrifuged, followed by transferring the resulting supernatant to a micro tube to store in a low temperature freezer (−80° C.) until use for animal experiments.
    • (2) Animal Experiments
  • Firstly, as a control group, mice, to which influenza virus alone was intranasally administered, was used. In an experimental group 1, poly-gamma-glutamic acid (γ-PGA) was administered to enhance immunity against virus, and then influenza virus was administered the next day, thus inhibiting viral infection. Specifically, in the experimental group 1, mice were anesthetized using diethyl ether for 30 seconds, and then, 30 μl γ-PGA (7,000 kDa) having a final concentration of 0.5% was administered to the nasal cavity of each mouse. The next day, influenza virus was simultaneously administered to the mice together with the same amount of γ-PGA.
  • As an experimental group 2, mice, to which γ-PGA and influenza virus were simultaneously administered on the day when the experimental group 1 was infected with virus, was used. Constitution of the experimental groups are shown in Table 2.
  • TABLE 2
    Constitution of the experimental groups
    Day of administration (γ-PGA or Virus)
    1 day before
    Group administration 0 day (D-day) Head
    1 γ-PGA γ-PGA + Virus volume A 5
    γ-PGA γ-PGA + Virus volume B 5
    2 — γ-PGA + Virus volume A 5
    — γ-PGA + Virus volume B 5
    Control group — Virus volume A 5
    — Virus volume B 5
    Virus volume A: 2.5 × 105 EID50,
    Virus volume B: 1.25 × 105 EID50
  • For viral infection, the experimental animals were anesthetized using diethyl ether for 30 seconds to intranasally administer 30 μl of virus to each mouse, and in the groups administered volume A of virus, 2.5×105 EID50 of virus was administered and in the groups administered volume B of virus, 1.25×105 EID50 of virus was administered.
  • As a result, as shown in FIG. 1, in the control group, all mice died on the 7th day after virus administration. In the experimental group to which γ-PGA and virus were simultaneously administered, 2 mice died on the 12th day after administration in the group administered volume A of virus. In experimental group 1 to which γ-PGA was administered one day before viral infection, mice survived more than 2 weeks after virus administration. It suggests that pre-administration of γ-PGA induces immunity to inhibit viral infection, as well as simultaneous administration helps each individual mouse to survive.
  • 1 week after intranasal administration of virus, one mouse per group was euthanized at an interval of 3 days (on the 7th day, on the 10th day, and on the 13th day after virus administration) to harvest lung tissue and serum.
  • Titers of influenza virus in lung tissue of mice according to dates and each group were measured by the following HA (Haemagglutination) test.
  • Lung tissue harvested from the dead mice and mice on the corresponding days, which are anesthetized using diethyl ether for 30 seconds, by opening thoracic cavity by a midline incision, was rapidly frozen in liquid nitrogen and stored at −80° C. until assayed for titers. The harvested lung tissue was immersed in PBS (500 μl) containing antibiotics and crushed with small metallic beads sterilized with steam of high-pressure and high-humidity for 3 minutes in a tissue homogenizer. The crushed tissue was centrifuged to obtain supernatant and diluted by log 10 dilution, and then the diluted solution was inoculated into 10-day-old embryonated eggs of white laying hens.
  • The inoculated embryonated eggs were cultured at 37° C. for 48 hours to harvest the allantoic fluid. 50 μl of the harvested allantoic fluid was added to the first well of a round-bottom 96 well plate, and next each well was log 2 diluted in the same volume of PBS, and then 50 μl PBS was discarded after dilution of the last well. Lastly, 50 μl of PBS containing 0.5% chicken erythrocytes, was added to each well and allowed to react for 40 minutes at room temperature.
  • Each titer is the value calculated from log 10 dilution of inoculum solution (200 μl).
  • N value is expressed as a logarithmic value (log10 N=10N).
  • TABLE 3
    Titers of influenza virus in lung tissue of mice
    Titers measured at various
    Inoculum days elapsed from infection
    Group volume the 7th day the 10th day the 13th day
    1 A 5 — —
    B 5 3 1
    2 A 3 — —
    B 3 4 3
    3 A 5.3 x x
    B 5 x x
  • Titer is the value calculated from log 10 dilution of inoculum solution (200 μl).
  • N value is expressed as a logarithmic value (log10N=10N).
  • As a result, as shown in Table 3, in the control group, the group administered volume A of virus showed a titer of 5.3, and the group administered volume B of virus showed a titer of 5, and an increase or decrease in the titer was not shown since all mice died. In the experimental group 1, the group administered volume B of virus showed a gradual decrease in titer with the passage of time. However, the titer was decreased a little in the experimental group 2. As a result, it was suggested that administration of γ-PGA helps an individual mouse overcome infectious disease caused by highly pathogenic virus. In addition, titer decrease was higher in the group immunized with γ-PGA 1 day before virus administration, suggesting that immunization with γ-PGA induces resistance against virus.
  • Antibody titers in sera of mice according to dates and each group were measured by the following HI (Haemagglutination Inhibition) test.
  • All sera were treated with RDE (receptor-destroying enzyme) extracted from Vibrio cholerae with a volume ratio of 1:3 (for example, adding 30 μl RDE to 10 μl serum), to culture for 18˜20 hours in a culture incubator at 37° C. 25 μl of each sample, from which non-specific activities of receptors in serum were inactivated, was serially diluted (log 2) in a round-bottom 96 well plate. Second, the same volume of 4HAU virus was added to serum samples and allowed to react for 30 minutes in an incubator at 37° C. Finally, 50 μl of PBS containing 0.5% chicken erythrocyte and allowed to react at room temperature for 40 minutes.
  • TABLE 4
    Titers of antibodies in mouse serum
    Titers measured at various days elapsed
    from infection
    Inoculum the 7th the 10th the 13th
    Group volume day day day the 15th day
    1 A 0 0 0 5
    B 0 0 0 3
    2 A 0 0 5 6
    B 0 0 2 3
    3 A 0 0 0 0
    B 0 0 0 0
  • Titer is the value calculated from log 10 dilution of inoculum solution (2000. N value is expressed as a logarithmic value (log10 N=10N)
  • As a result, as shown in Table 4, the antibody titer against virus increased in the experimental group to which virus and γ-PGA were simultaneously administered. In the experimental group 2, antibodies started to appear on the 13th day after administration, and increased until the 15th day. In the experimental group 1, antibodies started to appear on the 15th day. In the control group, since all mice died on the 7th day, only the titer in specimens was measured and antibodies against virus were not shown. In the group immunized with γ-PGA the day before virus administration, antibodies were produced relatively late compared to the experimental group 2, but the experimental group 1 showed higher antibody production than that of the group to which γ-PGA and virus were simultaneously administered.
  • From this results, it was confirmed that the γ-PGA according to the present invention had an immune enhancement effect against virus to inhibit viral infection.
    • Example 4 Immune Enhancement Effect 2 of γ-PGA Against Influenza Virus
  • In the present example, in order to examine an infection-inhibiting effect of γ-PGA specific to avian influenza virus, the animal's death, virus proliferation, and antibody production in experimental animals infected with influenza virus, were analyzed.
  • As influenza virus used as a pathogen, H1N1 high pathogenicity influenza virus strain (A/Puerto Rico/8/34 (H1N1)) was isolated from a mouse which was donated by Prof. Choi, Young-Ki of microbiological laboratory, College of Medicine, Chungbuk National University to amplify in Madin-Darby canine kidney (MDCK) cells to use, and 6-week-old female Balb/C mice were used as experimental animals.
  • An animal experiment was carried out as follows.
  • A control group was administered influenza virus alone, an experimental group 2 was administered γ-PGA twice, and then administered influenza virus, and an experimental group 3 was simultaneously administered γ-PGA and influenza virus.
  • Influenza virus and γ-PGA were intranasally administered to experimental mice after mice were anesthetized with diethyl ether for 30 minutes, at this time, 30 μl γ-PGA (7,000 kDa) with a final concentration of 0.5% was intranasally administered to each mouse, and 104 EID50 (30 μl) of virus was administered.
  • In the experimental group 3, mice simultaneously administered γ-PGA and influenza virus on the day when the experimental group 2 was infected with virus, were used.
  • 6 mice per group were used in order to measure mortality rate, 18 mice were used in order to measure changes in the amount of virus according to dates, and 15 mice were used as a control group for the experiment, and changes in body weight were monitored on a daily basis in each group to measure weight change rates as a pathogen indicator.
  • As a result, as shown in FIG. 2, in the control group, starting with the death of one mouse 1 week after virus administration, 3 mice died on the 9th day and, on the 12th day, 2 mice with severe pathogenicity remained alive. In the experimental groups 2 and 3, mice only showed mild disease symptoms, and survived more than 12 days after virus administration.
  • 1 week after intranasal administration of virus, 2 mice per group were euthanized at an interval of 2 days (on the 1st day, the 3rd day, the 5th day, the 7th day, the 9th day, and the 12th day after virus administration) to harvest lung tissue and serum of each mouse.
  • Titers of influenza virus in lung tissue of mice according to dates and each group were measured by HA (Haemagglutination) test as described in Example 2.
  • Each titer is the value calculated from log 10 dilution of inoculum solution (200 μl).
  • N value is expressed as a logarithmic value (log10 N=10N). The virus titer showed the maximum value of 5.5 on the 5th day after administering virus in the control group and the experimental group 3.
  • In the experimental group 2 immunized with γ-PGA before virus administration, the virus titer was relatively low on the first day after virus administration, increased until the 5th day, started to decrease after the 5th day of administration, rapidly decreased after the 7th day of administration, and virus was not detected anymore on the 12th day. In the experimental group 3 simultaneously administered poly-gamma-glutamic acid and virus, the titer was the same as that of the control group on the 5th day after administering virus, but started to decrease after the 5th day of administration, rapidly decreased on the 7th day after virus administration like the experimental group 2, and virus was not detected anymore on the 12th day. This suggests that the administered γ-PGA helps an individual mouse to resist viral infection, and thus is effective for an individual mouse to overcome viral infection due to enhanced immunity.
  • In order to measure weight change rates as a pathogen indicator, weight changes were monitored on a daily basis in each group (FIG. 4). Each value is expressed as a percentage of the decreased rate (weight measured after virus administration/weight measured before virus administration).
  • After virus administration, in the control group, it was observed that the body weight decrease started to increase rapidly after the 5th day of administration, and the mortality rate was more that 20% after the 7th day of administration. In the other two experimental groups, body weight decreased until the 7th day after virus administration, and started to increase after the 7th day of administration and mice recovered, which suggests that there is a correlation between mortality rates and virus titers in lung tissue after virus administration.
  • From this results, it was confirmed that the poly-gamma-glutamic acid according to the present invention has an immune enhancement effect against influenza virus to inhibit viral infection.
    • Example 5 Inducement of INF-β Secretion in a Macrophage
  • The effect of the inventive γ-PGA on activation of macrophages, which play an important role in virus inhibitory activity, a primary immune reaction of the immune system, was examined.
  • As an indicator for macrophage activation, the secretion of interferon beta (INF-β), one of cytokines secreted by macrophages, which mediates innate immune reaction, was examined.
  • For the examination, RAW 264.7 (ATCC TIB-71), which is a macrophage cell line of Balb/c mouse, was suspended in a DMEM (added with 100 U/ml penicillin-streptomycin, 10% FBS) medium and dispensed into a 6 well plate at a density of 5×105 cells/well to culture in a CO2 incubator for 12 hours, and then, γ-PGA (7,000 kDa) was diluted to concentrations of 0.1% and 0.5% in a DMEM medium containing no FBS, respectively, to culture for 12 hours.
  • During the culture, culture supernatants of each well were collected at 3, 6, 12, and 12 hours, and the same volume of culture broth as that of the collected culture supernatants, was added again. The amount of secreted INF-β in the collected supernatants was measured by ELISA kit (BD Bioscience, USA).
  • 100 μl standard solution of IFN-β and 100 μl of supernatant were added to a 96 well plate coated with anti-mouse monoclonal antibodies of IFN-β and allowed to react for 1 hour at room temperature, then washed 3 times with wash buffer (250 μl/well), and then 100 μl polyclonal antibodies of each biotinylated anti-mouse INF-β which is a primary antibody, were added and allowed to react for 1 hour at room temperature to wash 3 times with wash buffer (250 μl/well). After that, 100 avidin-horseradish peroxidase conjugate which is a secondary antibody, was added and allowed to react for 1 hour at room temperature to wash 3 times, and then allowed to react with a color development reagent, TMB solution for 15 minutes, followed by stopping the color development with 50 μl of stop solution, thus analyzing the amount of each INF-β by measuring at 450 nm by using an ELISA reader.
  • As a result, as shown in FIG. 5, it was observed that macrophages cultured together with γ-PGA started to secrete interferon beta 6 hours after the culture, and the secreted amount increased with the passage of time. The amount of secreted interferon beta increased as γ-PGA-concentration increased, suggesting that INF-β secretion is γ-PGA-concentration dependent.
  • It was confirmed that γ-PGA is highly effective to induce macrophage activation, and the macrophage activation is γ-PGA-concentration dependent.
  • As a result, it was found that γ-PGA according to the present invention induces the secretion of INF-β secreted by macrophages, which is an indicator of the activation of macrophages playing an important role in immune reaction and virus growth inhibition activity.
    • INDUSTRIAL APPLICABILITY
  • As described above, the present invention has the effect of providing the composition containing γ-PGA as an effective ingredient, which can be used as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.
  • While the present invention has been described with reference to the particular illustrative embodiment, it is not to be restricted by the embodiment but only by the appended claims. It is to be appreciated that those skilled in the art can change or modify the embodiment without departing from the scope and spirit of the present invention.

Claims (6)

1. A pharmaceutical composition for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
2. The composition according to claim 1, wherein the molecular weight of poly-gamma-glutamic acid is 1 kDa˜15,000 kDa.
3. The composition according to claim 1, wherein the virus is capable of inducing respiratory infection or systemic infection.
4. The composition according to claim 1, wherein the composition is a dispersive formulation in which poly-gamma-glutamic acid is diluted with ethanol.
5. A functional food for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
6. A feedstuff additive for inhibiting viral infection or preventing viral diseases, which comprises an effective dose of poly-gamma-glutamic acid.
US12/678,027 2007-09-13 2007-09-13 Composition for preventing virus infection comprising poly-gamma-glutamic acid Abandoned US20100256050A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2007/004419 WO2009035173A1 (en) 2007-09-13 2007-09-13 Composition for preventing virus infection comprising poly-gamma-glutamic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/004419 A-371-Of-International WO2009035173A1 (en) 2007-09-13 2007-09-13 Composition for preventing virus infection comprising poly-gamma-glutamic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/234,670 Continuation US9095605B2 (en) 2007-09-13 2011-09-16 Composition for preventing virus infection comprising poly-gamma-glutamic acid

Publications (1)

Publication Number Publication Date
US20100256050A1 true US20100256050A1 (en) 2010-10-07

Family

ID=40452160

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/678,027 Abandoned US20100256050A1 (en) 2007-09-13 2007-09-13 Composition for preventing virus infection comprising poly-gamma-glutamic acid
US13/234,670 Active 2028-04-05 US9095605B2 (en) 2007-09-13 2011-09-16 Composition for preventing virus infection comprising poly-gamma-glutamic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/234,670 Active 2028-04-05 US9095605B2 (en) 2007-09-13 2011-09-16 Composition for preventing virus infection comprising poly-gamma-glutamic acid

Country Status (8)

Country Link
US (2) US20100256050A1 (en)
EP (1) EP2187897B1 (en)
JP (1) JP5166533B2 (en)
CN (1) CN101873861A (en)
AU (1) AU2007358800B2 (en)
BR (1) BRPI0721960A2 (en)
CA (1) CA2699468A1 (en)
WO (1) WO2009035173A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095605B2 (en) 2007-09-13 2015-08-04 Bioleaders Corporation Composition for preventing virus infection comprising poly-gamma-glutamic acid
US20170296576A1 (en) * 2016-04-18 2017-10-19 Bioleaders Corporation Method for treating cervical intraepithelial neoplasia using poly-gamma- glutamic acid

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037843A (en) * 2009-07-16 2011-02-24 Kao Corp Agent for inhibiting increase in postprandial blood insulin level
EP2455089B1 (en) 2009-07-16 2016-05-18 Kao Corporation Inhibitor of blood gip level elevation
JP2011178764A (en) * 2010-03-04 2011-09-15 Ajinomoto Co Inc Intestinal bifidobacterium proliferation promoter and intestinal barrier function-improving agent
EP2664338B1 (en) 2011-01-12 2019-01-30 Kao Corporation Potassium polyglutamate for use in the treatment of obesity, diabetes, hypertriglyceridemia and hyperlipidemia
TWI568809B (en) * 2013-02-12 2017-02-01 東洋紡股份有限公司 Virus inactivating agent
KR102091588B1 (en) * 2013-05-27 2020-03-24 주식회사 바이오리더스 Composition for Dispersting or Hydrating Mucus Containing Poly gamma-glutamic acid
WO2016056681A1 (en) * 2014-10-06 2016-04-14 주식회사 바이오리더스 Cell surface expression vector of influenza virus antigen, and microorganism transformed thereby
KR102253324B1 (en) * 2019-11-27 2021-05-18 단디바이오사이언스 주식회사 A composition for preventing, alleviating or treating a respiratory disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127447A1 (en) * 2002-07-10 2006-06-15 Moon-Hee Sung Poly-gamma-glutamate having ultra high molecular weight and method for using the same
US20060134143A1 (en) * 2003-06-05 2006-06-22 Rachel Schneerson Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
KR20010078440A (en) 2001-01-11 2001-08-21 김형순,성문희 Bacillus subtilis var. chungkookjang Producing High Molecular Weight Poly-gamma-glutamic Acid
WO2005048918A2 (en) * 2003-07-30 2005-06-02 Merck & Co., Inc. Anthrax vaccine
KR100475406B1 (en) 2003-12-12 2005-03-14 주식회사 바이오리더스 Composition for Stimulating Immune Response Containing Poly-gamma-glutamic acid
KR100496606B1 (en) * 2004-07-02 2005-06-22 Bioleaders Corp Composition for anti-cancer comprising poly- -glutamic acid
JP2006036721A (en) * 2004-07-29 2006-02-09 Ajinomoto Co Inc Permeation and absorption promoting agent
KR100517114B1 (en) * 2005-02-25 2005-09-27 주식회사 바이오리더스 Composition for adjuvant containing poly-gamma-glutamic acid
EP1872793B1 (en) * 2005-04-20 2012-10-10 Mitsuru Akashi Polyamino acid for use as adjuvant
BRPI0721960A2 (en) 2007-09-13 2014-05-20 Bioleaders Corp COMPOSITION, FUNCTIONAL FOOD AND ACTIVE INGREDIENT FOR PREVENTION OF VIRAL INFECTION UNDERSTANDING POLY-GAMMA-GLUTYMIC ACID

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127447A1 (en) * 2002-07-10 2006-06-15 Moon-Hee Sung Poly-gamma-glutamate having ultra high molecular weight and method for using the same
US20060134143A1 (en) * 2003-06-05 2006-06-22 Rachel Schneerson Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095605B2 (en) 2007-09-13 2015-08-04 Bioleaders Corporation Composition for preventing virus infection comprising poly-gamma-glutamic acid
US20170296576A1 (en) * 2016-04-18 2017-10-19 Bioleaders Corporation Method for treating cervical intraepithelial neoplasia using poly-gamma- glutamic acid
US10485823B2 (en) * 2016-04-18 2019-11-26 Bioleaders Corporation Method for treating cervical intraepithelial neoplasia using poly-gamma- glutamic acid

Also Published As

Publication number Publication date
CA2699468A1 (en) 2009-03-19
BRPI0721960A2 (en) 2014-05-20
CN101873861A (en) 2010-10-27
JP2010539158A (en) 2010-12-16
EP2187897A4 (en) 2010-10-20
AU2007358800A1 (en) 2009-03-19
AU2007358800B2 (en) 2012-05-10
US20120010130A1 (en) 2012-01-12
EP2187897A1 (en) 2010-05-26
WO2009035173A1 (en) 2009-03-19
US9095605B2 (en) 2015-08-04
JP5166533B2 (en) 2013-03-21
EP2187897B1 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
US9095605B2 (en) Composition for preventing virus infection comprising poly-gamma-glutamic acid
US20190091324A1 (en) Nasal influenza vaccine composition
KR100873179B1 (en) Composition for Inhibiting Infection of Viruses Containing Polygammaglutamic Acid
KR101001767B1 (en) Lactobacillus luterii H. Y7501 having anti-influenza virus efficacy and product containing it as an active ingredient
JP7084627B2 (en) Composition for preventing viral infections
KR101160743B1 (en) Anti-viral agent against avian influenza virus comprising green tea
CN100572532C (en) A kind of duck plague vaccine and special strains thereof
CN101524537B (en) Influenza oral lozenge vaccine, influenza oral slow-release vaccine and preparation methods of the two
Webster et al. Vaccination as a strategy to reduce the emergence of amantadine-and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus
CN102258500B (en) Oral slow release influenza vaccine and preparation method thereof
KR102492769B1 (en) Composition for antiviral activity comprising fucosyllactose
TW200927928A (en) Inactivated influenza vaccine
TW202222327A (en) Use of lactic acid bacteria for manufacturing an antiviral composition
JP5372547B2 (en) Immunoglobulin A production promoter
US20210220311A1 (en) Application of valine in preparing medicine for treating or preventing avian influenza virus infection
KR20120065654A (en) A composition comprising sialic acid-containing whey protein for preventing animal feeding addition and inclused animal feeding of influenza virus infectious disease
CN104523745A (en) Virus infection prevention composition containing poly-gamma-glutamic acid
US20090175963A1 (en) Antiviral composition comprising lycoris squamigera extracts
KR102693277B1 (en) Compositions for the prevention or treatment of influenza virus infection
RU2796748C1 (en) AGENT WITH ANTIVIRAL ACTIVITY AGAINST INFLUENZA A AND SARS-CoV-2 VIRUSES
TW202142250A (en) Use of lactic acid bacteria for manufacturing an antiviral composition
KR102210919B1 (en) A composition for the improving, preventing and treating of influenza virus infection comprising polysaccharide fraction isolated from barley leaf
JP2012106976A (en) Preventive agent for infection by influenza virus
CN102727502B (en) Resisiting influenza virus compositions and diet product, feedstuff and pharmaceuticals
Dankar Studies on a Newly Emerging H9N2-avian Influenza Outbreak in Poultry of Lebanon

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOLEADERS CORPORATION, KOREA, DEMOCRATIC PEOPLE'S

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUNG, MOON-HEE;KIM, CHUL JOONG;POO, HARYOUNG;AND OTHERS;REEL/FRAME:024335/0641

Effective date: 20100401

Owner name: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUNG, MOON-HEE;KIM, CHUL JOONG;POO, HARYOUNG;AND OTHERS;REEL/FRAME:024335/0641

Effective date: 20100401

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION